semaglutide vomiting class action in michigan Ozempic Lawsuit – June 2026 Update A pilot program will cover
Description
The evidence for this is weak at best
subcutaneous immediate-release exenatide (10, 20, 40, and 60 g/d) twice daily, 1.8 kg (95% CI, 2.4 to 1.2 kg)
However, their differing effects on metabolism, appetite, and blood glucose mean that patients prescribed both medications require careful monitoring and individualised management plans
Constella (linaclotide) CHMP assessment report
